All Updates

All Updates

icon
Filter
FDA approval
Karius Receives FDA breakthrough designation for its DNA-based blood test
Precision Medicine
May 16, 2024
This week:
Funding
GrayMatter Robotics raises USD 45 million in Series B funding to accelerate AI-powered robotics solutions
Smart Factory
Jun 20, 2024
Funding
Vecna Robotics raises USD 100 million in Series C funding; appoints new COO
Logistics Tech
Jun 20, 2024
Funding
Vecna Robotics raises USD 100 million in Series C funding; appoints new COO
Smart Factory
Jun 20, 2024
Funding
FairNow raises USD 3.5 million to advance AI governance solutions
Generative AI Infrastructure
Jun 20, 2024
Partnerships
Gravitics develops testing gauntlet for larger spacecraft in collaboration with NASA
Space Travel and Exploration Tech
Jun 20, 2024
M&A
knownwell acquires Alfie Health to integrate AI in primary and obesity care services
Telehealth
Jun 20, 2024
Funding
Pomelo Care raises USD 46 million in Series B funding to expand virtual maternal care
Telehealth
Jun 20, 2024
Funding
Isar Aerospace raises EUR 65 million, backed by NATO Innovation Fund
Space Travel and Exploration Tech
Jun 20, 2024
Product updates
Beyond Meat releases new Beyond Sausage, expanding its Beyond IV product line
Plant-based Meat
Jun 20, 2024
Product updates
Funding
SurrealDB raises USD 20 million in Series A; launches beta version of Surreal Cloud
Data Infrastructure & Analytics
Jun 20, 2024
Precision Medicine

Precision Medicine

May 16, 2024

Karius Receives FDA breakthrough designation for its DNA-based blood test

FDA approval

  • Karius has gained breakthrough designation from the FDA for its DNA-based blood test. The test, known as the Karius Test, is designed to detect ~1,000 different pathogens and has been commercially available since 2017. Currently, it is being used at ~400 locations across the US.

  • The Karius Test is used primarily in cancer centers to monitor immunocompromised patients suspected of having potentially fatal lung conditions. The test is able to identify infectious agents including bacteria, fungi, parasites, and viruses from blood samples. The Karius test was reportedly able to identify the probable cause of pneumonia in 12% of patients in clinical studies.

  • Karius operates in the life sciences sector, focusing on infectious disease diagnostics through genomic insights. Its Karius Test is a liquid biopsy test that non-invasively detects ~1,000 pathogens from a single blood sample. This test uses advanced genomics and AI to analyze microbial cell-free DNA, providing diagnostic information that enables rapid treatment decisions.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.